Loading, Please Wait...
OCEANSIDE, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (USOTC:TSOI) announced today an additional expansion to their CTE portfolio of intellectual property with the filing of this new patent application.
This new and novel invention provides a means of preventing and/or reversing chronic traumatic encephalopathy in a patient through the modulation of their monocytes as well as their monocytic progenitors.
"Injuries to the head, in particular, traumatic brain injury (TBI) are a substantially important public health problem, affecting millions of people annually in the U.S. alone. TBI is classified on a spectrum ranging from mild to severe, with mild TBI (mTBI) accounting for a vast majority of TBI cases. Notably, the incidence of mild TBI is commonly regarded as under-reported, particularly in the context of sports competitions, where athletes may wish to avoid being forced to stop participation until completion of a formal medical evaluation and return to play protocol is completed," said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. "As a result, mild TBI has been referred to as a silent epidemic that desperately needs a voice."
"This invention relies on the capacity of certain neurogenesis progenitor cells in the form of "educated" monocytes to secrete into growth medium the growth factors and cytokines involved in neurogenesis in a time and concentration-dependent coordinated and appropriate sequence," said Dr. Thomas Ichim, Director of Therapeutic Solutions International and co-inventor with Mr. Dixon. "Most currently tested therapeutic approaches have focused on a single neurogenesis growth factor delivered to the tissue. This can be accomplished either by delivery of the end product (e.g., protein) or by gene transfer, using diverse vectors. However, it is believed that complex interactions among several growth factor systems are probably necessary for the initiation and maintenance of new neuron formation," added Dr. Ichim.
"The typical head impact in mild TBI induces rapid percussive and/or torsional (rotational) damage to the brain, leading to bruising and hemorrhage with direct brain cell loss, a type of injury that is known to persist for years. Furthermore, repetitive mild TBI is associated with serious long-term sequelae including post-concussive syndrome and chronic traumatic encephalopathy (CTE), the latter often leading to cognitive impairment, neuropsychiatric symptoms, dementia, and pugilistic parkinsonism. Currently, there is a need to treat CTE with novel approaches," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "This new technology does just that stimulating neuroregeneration and decreasing inflammation in patients with CTE."
Since September 2018 the Company has filed 3 other patent applications for CTE related technologies. These include "Pterostilbene and Compositions Thereof for Prevention and Treatment of Chronic Traumatic Encephalopathy", "Treatment of Chronic Traumatic Encephalopathy via RNA Administration", "Autologous Neurogenic Cells and Uses Thereof for Professional Athletes at Risk of Chronic Traumatic Encephalopathy" and today's filing titled "Prevention and Reversion of Chronic Traumatic Encephalopathy through Administration of "Educated" Monocytes and Progenitors Thereof". In addition to these the Company also recently announced the licensing of mesenchymal stem cells for use in CTE and TBI under Right To Try.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene visit www.nanostilbene.com.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.